Today, for the first time, Metamark presents results from the clinical validation study that showed ProMark™, the first and only proteomic-based imaging biopsy test, achieved its primary endpoint by accurately differentiating between aggressive and non-aggressive forms of prostate cancer at early stages of disease. ProMark™ was shown to predict which patients have low-risk disease with a sensitivity of 90 percent or better, confidently identifying patients who are appropriate for active surveillance or need aggressive therapy. The data are being presented at the 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO).
"These results reinforce ProMark™ as a critical tool that has the potential to improve prostate cancer care by fulfilling the unmet need for more precise prognostic testing, which may benefit a significant number of the more than 200,000 men in the U.S. diagnosed annually who may be appropriate for active surveillance," said Fred Saad, M.D., F.R.C.S., Professor and Chief, Division of Urology, Director of Urologic Oncology, University of Montreal Hospital Center. "ProMark™ offers the oncology healthcare community a novel prognostic option to help confidently differentiate patients with more aggressive cancers from those with less aggressive disease, thereby enabling more personalized treatment decisions for our patients."
The results being presented are a culmination of three clinical studies. The first study identified 12 biomarkers that predicted both lethal outcome and prostate cancer pathology, and of those, eight were targeted in a clinical development biopsy study as the final subset for the ProMark™ test.
The third, blinded clinical validation study of ProMark™, which analyzed 274 prostate cancer biopsies, accurately predicted the overall prostate cancer pathology for patients with biopsy Gleason grades of 3+3favorable' cases (surgical Gleason score 3+3 or 3+4; organ-confined diseaseunfavorable' cases (greater than or equal to T3a, N, or M or surgical Gleasons ratios lowest to highest quartile of 5.
Researchers found that patients with low-risk ProMark™ scores (<0.33) were accurately identified as having favorable disease 81 percent of the time, with 90 percent specificity, while high-risk scores (>0.8) indicating non-favorable disease were predicted 77 percent of the time. Importantly, the ProMark™ test was found to provide additional, independent prediction relative to standard risk-stratification systems, including National Comprehensive Cancer Network (NCCN) guidelines, the D'Amico system, and CAPRA, all using Prostate-Specific Antigen (PSA) levels, Gleason grades and T stage to group men as low, intermediate, or high-risk.
"A key challenge in treating men with prostate cancer is determining whether they need aggressive therapy, or if active surveillance is appropriate. Current clinical and pathological parameters are insufficient in predicting the risk of aggressive cancer for early stage cancer patients," said Peter Blume-Jensen, M.D., Ph.D., Senior Vice President and Chief Scientific Officer at Metamark. "ProMark™ was developed with the specific purpose to address this need. This latest data is a significant milestone for Metamark as it indicates ProMark™ can be used as an objective aid in decision making together with standard-of-care for prostate cancer prognosis, and thereby help maintain a higher quality of life for patients by avoiding unnecessary aggressive therapy, like surgical prostatectomy or radiation."